Stock listing

Dusseldorf:9Y4 Ryvu Therapeutics SA Aktie

German listing (Dusseldorf) of Ryvu Therapeutics SA · home listing GPW:RVU

Follow Ryvu Therapeutics SA into a list and get an email when it puts out news.

Home listing price · GPW:RVU

16.18 PLN -0.72 (-4.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, GPW:RVU

Past year -32.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
16.02 – 16.86 PLNNov 20, 2026
Volume
19,982 sharesNov 20, 2026
Market cap
374.1M PLNAt the close on Nov 20, 2026 · price × 23.12M shares outstanding
52-week range
13.64 – 31.90 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
409,433 PLNMedian day 17,560 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Ryvu Therapeutics SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
GPW:RVU · Home16.18 PLN-0.72 (-4.3%)19,98216.6216.8616.0216.90Close on Nov 20, 2026
Frankfurt:9Y4€3.62 EUR-0.025 (-0.7%)—€3.62€3.62€3.62€3.645Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:RVU · PLN, adjusted for splits

DayCloseChange%OpenHighLowVolume
16.18-0.72-4.3%16.6216.8616.0219,982
16.90+0.02+0.1%16.8617.1616.5013,144
16.88-0.72-4.1%17.5017.5016.5016,747
17.60-0.40-2.2%17.4617.8017.2012,652
18.00+0.28+1.6%17.7218.1417.6215,674
17.72+0.52+3.0%17.2418.1016.9226,277
17.20+0.88+5.4%16.3217.2216.2216,298
16.32-0.12-0.7%16.4416.6016.2411,100
16.44-0.38-2.3%16.6817.0216.4012,810
16.82+0.26+1.6%16.6817.4016.4215,479
16.56+0.46+2.9%16.1416.9216.0013,705
16.10-0.12-0.7%16.5016.5016.0219,060
16.22-0.76-4.5%16.7016.9415.9230,708
16.98-0.82-4.6%17.8017.8616.5275,603
17.80-0.42-2.3%18.0218.4417.5238,748
18.22-0.38-2.0%18.7818.7818.0420,710
18.60-0.06-0.3%18.7818.8618.0025,417
18.66+0.88+4.9%17.9618.9017.78125,376
17.78+0.08+0.5%17.7017.9817.4037,101
17.70+0.32+1.8%17.5218.0217.3429,651
17.38+0.32+1.9%17.0617.8817.0612,759
17.06-0.74-4.2%17.9017.9016.8017,474
17.80-0.24-1.3%18.0818.0816.2827,023
18.04+0.60+3.4%17.3018.0617.3040,385
17.44+0.54+3.2%17.8017.9017.2228,966
16.90-0.30-1.7%17.1017.1816.6017,891
17.20+0.06+0.4%17.3817.5016.9827,088
17.14+0.64+3.9%16.6217.1816.5217,560
16.50+0.22+1.4%16.3016.6016.2014,498
16.28+0.22+1.4%16.1416.3616.0011,999
16.06+0.08+0.5%16.1016.3015.8019,528
15.98+0.18+1.1%15.8016.0015.665,930
15.80+0.30+1.9%16.0016.0015.445,928
15.50-0.12-0.8%15.5815.6615.489,673
15.62-0.02-0.1%15.9016.0015.547,133
15.64-0.26-1.6%16.0016.0015.627,803
15.90-0.18-1.1%16.0816.0815.628,372
16.08+0.14+0.9%16.0216.1415.869,037
15.94+0.02+0.1%15.9216.1015.748,764
15.92+0.08+0.5%15.8415.9815.708,645
15.84-0.16-1.0%16.1016.2015.8213,162
16.00+0.10+0.6%16.0016.1815.8615,979
15.90+0.10+0.6%16.2016.3415.8234,914
15.80-0.52-3.2%16.3216.9815.6055,241
16.32-0.38-2.3%16.6216.7616.0228,245
16.700.000.0%16.7616.7616.507,545
16.70-0.28-1.6%16.9416.9416.6029,588
16.98-0.06-0.4%17.0617.1816.944,710
17.04-0.32-1.8%17.3017.3816.9818,452
17.36-0.24-1.4%17.5217.6017.0216,745
17.60-0.30-1.7%17.9818.4217.6035,690
17.90+0.58+3.3%17.5017.9217.3625,003
17.32+0.24+1.4%17.0817.3216.7213,331
17.08+0.10+0.6%16.9817.1016.7011,524
16.98-0.38-2.2%17.4217.6016.7217,307
17.36-0.02-0.1%17.1017.3616.5248,909
17.38-0.30-1.7%17.6817.6817.1028,925
17.68-0.70-3.8%18.3018.3017.5821,035
18.380.000.0%18.3018.4818.088,043
18.38-0.12-0.6%18.2618.4618.0212,179
18.50+0.10+0.5%18.4018.5418.0037,983
18.40-0.40-2.1%18.9018.9018.1027,917
18.80+0.70+3.9%18.1018.8818.1036,665
18.10-0.32-1.7%18.6018.6017.3264,029
18.42-0.14-0.8%18.9219.3818.3038,418
Ticker
Dusseldorf:9Y4
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Ryvu Therapeutics SA news

Ryvu Therapeutics SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in all · newest May 16, 2024 · oldest 2022
Decks
21 decks · latest November 2026

Where Ryvu Therapeutics SA is listed

ListingExchangeCountryCurrency
GPW:RVU · Home listingGPWPolandPLN
Lang & Schwarz:A1JUH2Lang & SchwarzGermanyEUR
LS Exchange:A1JUH2LS ExchangeGermanyEUR
LSE:0RKTLSEUnited KingdomPLN
Frankfurt:9Y4FrankfurtGermanyEUR
Stuttgart:9Y4StuttgartGermanyEUR
Dusseldorf:9Y4 · This pageDusseldorfGermanyEUR

Valuation

EV/sales 6.0× against a median of 0.6×: the highest of 5 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
374.3M PLN
P/E
Loss
EV/sales
6.0×
EV/EBITDA
Negative EBITDA
Price/book
13.2×
Gross margin
−49.0%
Operating margin
−134.7%
Net margin
−109.9%
Debt to equity
2.6×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Ryvu Therapeutics SA · GPW:RVUUS$92.14MUS$92.19Mn/a6.0×n/a13.2×−109.9%2.6×n/a
Allergy Therapeutics plc · LSE:AGYUS$95.27MUS$117.1Mn/a1.6×n/a17.1×−72.9%6.3×n/a
Voyager Therapeutics, Inc. · NASDAQ:VYGRUS$95.21M−US$11.60Mn/a−0.5×n/a0.7×−416.3%0.0×1.45
Outlook Therapeutics, Inc. · NASDAQ:OTLKUS$94.94MUS$83.70Mn/an/an/an/an/an/a1.10
Molecular Partners AG · SIX:MOLNUS$93.53M−US$4.92Mn/an/an/a1.0×n/a0.0×n/a
Sunhawk Vision Biotech, Inc. · TPEX:7759US$93.04MUS$82.43Mn/an/an/a7.3×n/a0.0×n/a
HLB Life Science Co.,Ltd. · KRX:067630US$92.22MUS$125.9Mn/a3.1×n/a0.4×−60.9%0.2×n/a
Brii Biosciences Limited · HKEX:2137US$91.58M−US$173.2Mn/a−63.7×n/a0.3×n/a0.0×n/a
TWi Biotechnology, Inc · TPEX:6610US$91.56MUS$88.17Mn/an/an/a6.3×n/a0.0×n/a
NeOnc Technologies Holdings, Inc. · NASDAQ:NTHIUS$90.88MUS$85.02Mn/an/an/an/an/an/a1.44
Zura Bio Limited · NASDAQ:ZURAUS$89.63M−US$98.02Mn/an/an/a0.5×n/a0.0×1.52
Median of the othersUS$92.63MUS$83.06M0.6×0.8×−72.9%0.0×1.44

Forecasts

Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
29.90 PLN · Analysts' mean
EPS, year to Dec 2026
-1.88 · 2 analysts
Revenue, year to Dec 2026
92M · 1 analyst

Team and board

OfficerRole
Pawel PrzewiezlikowskiChief Executive Officer
Kamil SitarzChief Operating Officer
Hendrik NogaiChief Medical Officer
Justyna ŻółtekChief People Officer
Krzysztof BrzozkaChief Scientific Officer

Events

QuarterResultsShare move
Q4 2024Mar 13, 2025 · Before open−2.2%
Q3 2024Nov 7, 2024+8.3%
Q1 2024May 15, 2024 · Before open+3.1%
Q4 2023Mar 13, 2024 · Before open−2.6%
Q3 2023Nov 29, 2023 · After close−1.5%
Q2 2023Sep 13, 2023 · Before open+0.7%
Q1 2023May 16, 2023 · After close−4.1%
Q4 2022Mar 24, 2023 · After close−3.7%
Q3 2022Nov 23, 2022 · After close+0.2%
Q2 2022Sep 28, 2022 · After close−0.6%
All 16 quarters
QuarterResultsShare move
Q1 2022May 18, 2022 · After close−4.4%
Q4 2021Mar 15, 2022 · Before open−0.4%
Q3 2021Nov 10, 2021 · After close−0.6%
Quarter to Jun 30, 2021Sep 8, 2021 · After close−1.7%
Quarter to Mar 31, 2021May 12, 2021 · Before open+2.0%
Quarter to Dec 31, 2020Mar 16, 2021 · After close−0.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck41 slidesNovember 2026
Investor Presentation (September 2026)Investor deck40 slidesSeptember 2026
Investor Presentation (June 2025)Investor deck49 slidesJune 2025
Investor Presentation (May 2025)Investor deck50 slidesMay 7, 2025
Investor Presentation (March 2025)Investor deck48 slidesMarch 2025
Investor Presentation (July 2024)Investor deck48 slidesJuly 2024
Investor Presentation (June 2024)Investor deck48 slidesJune 2024
Investor Presentation (April 2024)Investor deck46 slidesApril 2024
Investor Presentation (March 2024)Investor deck46 slidesMarch 2024
Investor Presentation (January 2024)Investor deck46 slidesJanuary 2024
All 21 decks
DeckKindSlidesDate
Investor Presentation (November 2023)Investor deck44 slidesNovember 2023
Investor Presentation (October 2023)Investor deck44 slidesOctober 2023
Investor Presentation (September 2023)Investor deck41 slidesSep 19, 2023
Investor Presentation (August 2023)Investor deck42 slidesAugust 2023
EHA 2023Conference30 slidesJun 9, 2023
Investor Presentation (May 2023)Investor deck44 slidesMay 2023
Investor Presentation (December 2022)Investor deck46 slidesDecember 2022
Investor Presentation (November 2022)Investor deck45 slidesNovember 2022
Investor Presentation (August 2022)Investor deck43 slidesAugust 2022
Webinar: Podstawy transferu wiedzy i technologii (December 2021)Conference31 slidesDec 1, 2021
Investor Presentation (July 2020)Investor deck54 slidesJuly 2020

Open Decks

Financials

Annual, in PLN

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue62.3M78.0M46.9M38.8M11.2M15.4M42.6M77.2M87.8M48.1M
Cost of revenue179.3M19.6M17.6M17.4M13.7M8.76M92.7M29.7M25.9M16.9M
Gross profit-117.0M58.4M29.3M21.4M-2.54M6.65M-50.2M47.6M61.9M31.3M
Research and development26.0M15.0M13.0M67.6M53.9M27.1M17.3M
Selling, general and administrative5.56M4.33M5.47M55.8M22.1M17.9M10.5M
Operating income-122.2M-122.1M-100.9M-78.4M-103.8M-35.7M-45.1M-13.6M12.6M-1.21M
Depreciation and amortization9.44M10.5M11.0M12.9M12.6M12.4M7.99M7.09M5.24M3.62M
EBITDA-112.7M-111.6M-90.0M-65.5M-91.2M-23.3M-37.2M-6.52M17.9M2.40M
Interest expense8.80M3.81M97.0K1.09M442.0K387.4K398.3K291.5K231.2K35.8K
Income before tax-101.1M-111.1M-92.1M-79.2M-79.0M-30.6M-36.0M8.99M9.60M-1.28M
Income tax88.0K297.0K4.59M115.9K1.07M-30.0K8.09M2.87M-3.97M
Net income-101.2M-111.4M-92.1M-83.8M-79.1M-31.7M-36.0M-106.3K6.41M2.72M
Earnings per share, basic-4.38-4.82-4.02-4.57-4.31-1.89-2.25-0.010.470.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents59.6M160.1M57.9M101.9M83.2M136.2M72.1M110.4M36.1M29.1M
Short-term investments48.1M65.9M175.7M528.0K4.99M25.0M-196.0K-196.0K
Receivables20.1M20.9M9.19M5.05M11.7M7.95M15.0M21.4M19.8M16.4M
Inventory1.33M1.21M2.12M1.76M1.96M1.68M1.59M1.99M1.59M1.40M
Current assets139.3M272.4M278.4M367.9M104.2M172.4M90.0M173.2M59.9M47.7M
Property, plant and equipment91.2M91.2M66.2M39.7M31.4M21.8M
Goodwill280.7K280.7K280.7K
Total assets224.4M378.8M403.2M475.0M228.8M295.6M182.9M255.7M103.6M89.1M
Accounts payable16.2M31.1M23.1M12.6M11.7M6.26M13.4M16.7M9.37M6.79M
Current liabilities61.6M107.9M69.7M44.8M36.2M33.8M30.6M35.6M26.8M18.9M
Long-term debt70.3M73.3M00742.4K1.55M2.36M3.17M3.98M4.79M
Total debt71.7M75.5M906.0K2.77M5.07M7.41M9.22M13.5M7.99M9.62M
Total liabilities153.7M234.9M143.6M131.6M59.4M71.9M63.1M60.8M39.6M33.4M
Shareholders' equity53.8M143.9M259.6M343.4M161.3M223.7M119.8M191.9M62.3M55.4M
Shares outstanding23.1M23.1M22.9M18.3M18.4M16.8M16.0M15.5M13.8M13.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-110.3M-129.5M-84.5M21.3M-57.9M-10.6M-17.4M-36.4M11.0M-6.28M
Capital spending-7.47M-5.90M-8.58M-9.29M-12.0M-34.2M-24.0M-23.4M-21.6M-21.2M
Free cash flow-117.8M-135.4M-88.1M12.0M-69.8M-44.8M-41.4M-59.9M-10.6M-27.5M
Cash from investing13.3M137.2M-195.5M690.0K8.06M-55.9M-7.94M-37.2M-21.5M-18.4M
Cash from financing-3.05M94.2M240.8M-2.46M-3.17M130.7M2.59M147.9M17.6M25.0M
Share buybacks143.1M-2.99M134.2M935.9K327.9K
Change in cash-100.5M102.1M-44.0M18.7M-53.0M64.1M-22.8M74.2M7.03M288.1K

Open Financials

Cap table

Built by 6ix from Ryvu Therapeutics SA’s releases

Common shares
23,120,148
Fully diluted
23,120,148

Fully diluted

LineShares
Common shares23,120,148

Share count over time

CountShares
Nov 22, 202623,120,148

Open Cap table

Shareholders

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF10,061US$36,830Jun 30, 2026
Emerging Markets Core Equity 2 Portfolio3,875US$15,296Jul 31, 2026
State Street(R) SPDR(R) Portfolio Europe ETF381US$1,395Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Hendrik NogaiChief Medical Officer · Since at least Nov 5, 2026
Justyna ŻółtekChief People Officer · Since at least Nov 5, 2026
Kamil SitarzChief Operating Officer · Since at least Nov 5, 2026
Krzysztof BrzozkaChief Scientific Officer · Since at least Nov 5, 2026
Pawel PrzewiezlikowskiChief Executive Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Ryvu Therapeutics SA.